iShares S&P 100
2.70 (1.50%)


Draw Mode:

Volume 126,251
Bid Price
Ask Price
News -
Day High 182.95


52 Week Range


Day Low 181.15
Company Name Etf Ticker Symbol Market Type
iShares S&P 100 OEF AMEX Exchange Traded Fund
  Price Change Change Percent Etf Price Last Traded
2.70 1.5% 182.95 15:41:05
Open Price Low Price High Price Close Price Prev Close
181.86 181.15 182.95 180.25
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,939 126,251  181.91  22,966,452 - 157.57 - 213.25
Last Trade Time Type Quantity Etf Price Currency
15:41:05 1  182.9209 USD

iShares S&P 100 Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 7.40B 40.45M 40.45M  -  - - 20.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
-  - 1.47% 12/13/22 - -

more financials information »

News iShares S&P 100

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No OEF Message Board. Create One! See More Posts on OEF Message Board See More Message Board Posts

OEF Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week176.56183.03174.62178.71309,8376.393.62%
1 Month180.63183.18172.04178.16227,9782.321.28%
3 Months170.55187.72167.53178.11246,23812.407.27%
6 Months176.40187.72157.57173.83317,8516.553.71%
1 Year204.97213.25157.57179.92322,267-22.02-10.74%
3 Years105.95222.35101.8696172.41320,35277.0072.68%
5 Years119.83222.35101.8696144.90444,27863.1252.67%

The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM. The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-.